Text Size

Randomised Double Blind Placebo Controlled Cross Over Design of the Efficacy of Topical Morphine for Inflammatory Pain in Children With Epidermolysis Bullosa

This study has been completed.
Sponsor:
Information provided by:
Institute of Child Health
ClinicalTrials.gov Identifier:
NCT00231517
First received: October 3, 2005
Last updated: October 11, 2006
Last verified: October 2005
History of Changes
  Purpose

Randomised Double blind placebo controlled cross over design study of the efficacy of morphine for inflammatory pain in children with Epidermolysis Bullosa


Condition Intervention Phase
Epidermylosis Bullosa
 Drug: topical opiod
Drug: morphine sulphate in intrasite gel
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Institute of Child Health:

  Eligibility

Ages Eligible for Study:   4 Years to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • children under 18 years epidermolysis wounds requiring dressing changes
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00231517

Locations
United Kingdom
Great Ormond Street Hospital and the Institute of Child health
London, United Kingdom, WC1N 1EH
Sponsors and Collaborators
Institute of Child Health
Investigators
Principal Investigator: Richard Howard, Prof Institute of Child Health
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00231517     History of Changes
Other Study ID Numbers: 01MH17
Study First Received: October 3, 2005
Last Updated: October 11, 2006
Health Authority: United Kingdom: Research Ethics Committee

Additional relevant MeSH terms:
Epidermolysis Bullosa
Skin Abnormalities
Congenital Abnormalities
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases
Skin Diseases, Vesiculobullous
Morphine
Analgesics, Opioid
 Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Central Nervous System Depressants
Narcotics

ClinicalTrials.gov processed this record on May 23, 2013